Itamar Medical (NASDAQ:ITMR) Vs. USNA, TRIL, GBT, SAVA, LNTH, HSKA, IRWD, NSTG, VCEL, and MORF
Should you be buying Itamar Medical stock or one of its competitors? The main competitors of Itamar Medical include USANA Health Sciences (USNA), Trillium Therapeutics (TRIL), Global Blood Therapeutics (GBT), Cassava Sciences (SAVA), Lantheus (LNTH), Heska (HSKA), Ironwood Pharmaceuticals (IRWD), NanoString Technologies (NSTG), Vericel (VCEL), and Morphic (MORF). These companies are all part of the "medical" sector.
Itamar Medical vs.
Trillium Therapeutics (NASDAQ:TRIL) and Itamar Medical (NASDAQ:ITMR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, community ranking, earnings, valuation and risk.
Trillium Therapeutics received 269 more outperform votes than Itamar Medical when rated by MarketBeat users. Likewise, 72.94% of users gave Trillium Therapeutics an outperform vote while only 60.29% of users gave Itamar Medical an outperform vote.
Trillium Therapeutics currently has a consensus target price of $20.30, indicating a potential upside of 10.09%. Itamar Medical has a consensus target price of $31.37, indicating a potential upside of 2.35%. Given Trillium Therapeutics' higher possible upside, equities analysts plainly believe Trillium Therapeutics is more favorable than Itamar Medical.
Trillium Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the S&P 500. Comparatively, Itamar Medical has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500.
Itamar Medical has higher revenue and earnings than Trillium Therapeutics. Itamar Medical is trading at a lower price-to-earnings ratio than Trillium Therapeutics, indicating that it is currently the more affordable of the two stocks.
Itamar Medical's return on equity of 0.00% beat Trillium Therapeutics' return on equity.
In the previous week, Itamar Medical had 2 more articles in the media than Trillium Therapeutics. MarketBeat recorded 2 mentions for Itamar Medical and 0 mentions for Trillium Therapeutics. Itamar Medical's average media sentiment score of 0.49 beat Trillium Therapeutics' score of 0.00 indicating that Itamar Medical is being referred to more favorably in the news media.
87.2% of Trillium Therapeutics shares are held by institutional investors. Comparatively, 42.2% of Itamar Medical shares are held by institutional investors. 9.1% of Trillium Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Trillium Therapeutics beats Itamar Medical on 9 of the 15 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ITMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Itamar Medical (NASDAQ:ITMR) vs. Its Competitors
Itamar Medical Competitors List
